ID PLCD4_RAT Reviewed; 772 AA. AC Q62711; Q63693; DT 02-OCT-2007, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 24-JAN-2024, entry version 159. DE RecName: Full=1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-4 {ECO:0000305}; DE EC=3.1.4.11 {ECO:0000269|PubMed:8550586}; DE AltName: Full=Phosphoinositide phospholipase C-delta-4; DE AltName: Full=Phospholipase C-delta-4; DE Short=PLC-delta-4; GN Name=Plcd4 {ECO:0000312|RGD:621025}; OS Rattus norvegicus (Rat). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae; OC Murinae; Rattus. OX NCBI_TaxID=10116; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), FUNCTION, ENZYME RP ACTIVITY, COFACTOR, AND TISSUE SPECIFICITY. RC STRAIN=Sprague-Dawley; TISSUE=Brain; RX PubMed=8550568; DOI=10.1074/jbc.271.1.25; RA Lee S.B., Rhee S.-G.; RT "Molecular cloning, splice variants, expression, and purification of RT phospholipase C-delta 4."; RL J. Biol. Chem. 271:25-31(1996). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ENZYME ACTIVITY, SUBCELLULAR RP LOCATION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, INDUCTION, AND CATALYTIC RP ACTIVITY. RC STRAIN=Donryu; RX PubMed=8550586; DOI=10.1074/jbc.271.1.355; RA Liu N., Fukami K., Yu H., Takenawa T.; RT "A new phospholipase C delta 4 is induced at S-phase of the cell cycle and RT appears in the nucleus."; RL J. Biol. Chem. 271:355-360(1996). RN [3] RP ALTERNATIVE SPLICING (ISOFORM 4), FUNCTION (ISOFORM 4), AND MUTAGENESIS OF RP ARG-36. RX PubMed=9915823; DOI=10.1074/jbc.274.5.2872; RA Nagano K., Fukami K., Minagawa T., Watanabe Y., Ozaki C., Takenawa T.; RT "A novel phospholipase C delta4 (PLCdelta4) splice variant as a negative RT regulator of PLC."; RL J. Biol. Chem. 274:2872-2879(1999). RN [4] RP DOMAIN C2, AND MUTAGENESIS OF LYS-714; SER-717 AND ARG-718. RX PubMed=11706040; DOI=10.1074/jbc.m109705200; RA Ananthanarayanan B., Das S., Rhee S.-G., Murray D., Cho W.; RT "Membrane targeting of C2 domains of phospholipase C-delta isoforms."; RL J. Biol. Chem. 277:3568-3575(2002). RN [5] RP DOMAIN PH, AND SUBCELLULAR LOCATION. RX PubMed=15037625; DOI=10.1074/jbc.m312772200; RA Lee S.B., Varnai P., Balla A., Jalink K., Rhee S.G., Balla T.; RT "The pleckstrin homology domain of phosphoinositide-specific phospholipase RT Cdelta4 is not a critical determinant of the membrane localization of the RT enzyme."; RL J. Biol. Chem. 279:24362-24371(2004). RN [6] RP SUBCELLULAR LOCATION. RX PubMed=17063484; DOI=10.1002/jcb.21048; RA Lo Vasco V.R., Fabrizi C., Artico M., Cocco L., Billi A.M., Fumagalli L., RA Manzoli F.A.; RT "Expression of phosphoinositide-specific phospholipase C isoenzymes in RT cultured astrocytes."; RL J. Cell. Biochem. 100:952-959(2007). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-445 AND SER-458, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=22673903; DOI=10.1038/ncomms1871; RA Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C., RA Olsen J.V.; RT "Quantitative maps of protein phosphorylation sites across 14 different rat RT organs and tissues."; RL Nat. Commun. 3:876-876(2012). CC -!- FUNCTION: Hydrolyzes the phosphatidylinositol 4,5-bisphosphate (PIP2) CC to generate 2 second messenger molecules diacylglycerol (DAG) and CC inositol 1,4,5-trisphosphate (IP3). DAG mediates the activation of CC protein kinase C (PKC), while IP3 releases Ca(2+) from intracellular CC stores. Required for acrosome reaction in sperm during fertilization, CC probably by acting as an important enzyme for intracellular Ca(2+) CC mobilization in the zona pellucida-induced acrosome reaction. May play CC a role in cell growth. Modulates the liver regeneration in cooperation CC with nuclear PKC. Overexpression up-regulates the Erk signaling pathway CC and proliferation. {ECO:0000269|PubMed:8550568}. CC -!- FUNCTION: [Isoform 4]: Has no enzyme activity and acts as a negative CC regulator of phospholipase C, with a preference for thePLC-delta CC family. {ECO:0000269|PubMed:9915823}. CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5- CC bisphosphate) + H2O = 1D-myo-inositol 1,4,5-trisphosphate + a 1,2- CC diacyl-sn-glycerol + H(+); Xref=Rhea:RHEA:33179, ChEBI:CHEBI:15377, CC ChEBI:CHEBI:15378, ChEBI:CHEBI:17815, ChEBI:CHEBI:58456, CC ChEBI:CHEBI:203600; EC=3.1.4.11; CC Evidence={ECO:0000269|PubMed:8550586}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:33180; CC Evidence={ECO:0000305|PubMed:8550586}; CC -!- CATALYTIC ACTIVITY: CC Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + H2O = CC 1D-myo-inositol 1-phosphate + a 1,2-diacyl-sn-glycerol + H(+); CC Xref=Rhea:RHEA:43484, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, CC ChEBI:CHEBI:17815, ChEBI:CHEBI:57880, ChEBI:CHEBI:58433; CC Evidence={ECO:0000250|UniProtKB:Q9BRC7}; CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43485; CC Evidence={ECO:0000250|UniProtKB:Q9BRC7}; CC -!- COFACTOR: CC Name=Ca(2+); Xref=ChEBI:CHEBI:29108; CC Evidence={ECO:0000305|PubMed:8550568}; CC Note=Binds 3 Ca(2+) ions per subunit. Two of the Ca(2+) ions are bound CC to the C2 domain. {ECO:0000305|PubMed:8550568}; CC -!- SUBUNIT: Interacts with GRIP1 (By similarity). Interacts (via GBA CC motif) with guanine nucleotide-binding protein G(i) alpha subunit GNAI3 CC (inactive GDP-bound form); low-affinity interaction (By similarity). CC {ECO:0000250|UniProtKB:Q8K3R3, ECO:0000250|UniProtKB:Q9BRC7}. CC -!- SUBCELLULAR LOCATION: Endomembrane system; Peripheral membrane protein. CC Nucleus. Cytoplasm. Endoplasmic reticulum. Note=Localizes primarily to CC intracellular membranes mostly to the endoplasmic reticulum. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=4; CC Name=1; CC IsoId=Q62711-1; Sequence=Displayed; CC Name=2; Synonyms=ALT I; CC IsoId=Q62711-2; Sequence=VSP_028508; CC Name=3; Synonyms=ALT II; CC IsoId=Q62711-3; Sequence=VSP_028509; CC Name=4; Synonyms=ALT III; CC IsoId=Q62711-4; Sequence=VSP_028507; CC -!- TISSUE SPECIFICITY: Present at high level in testis. Also present in CC brain > skeletal muscle > thyroid gland > stomach > thymus > aorta > CC heart (at protein level). Highly expressed in regenerating liver. CC Isoform 4 is weakly expressed compared to other isoforms but is CC expressed at high level in some neural cells. CC {ECO:0000269|PubMed:8550568, ECO:0000269|PubMed:8550586}. CC -!- DEVELOPMENTAL STAGE: Increases at the transition from G1- to S-phase, CC and the continues to the end of M-phase. Almost disappears when cells CC reenter the next G1-phase. {ECO:0000269|PubMed:8550586}. CC -!- INDUCTION: By serum treatment. {ECO:0000269|PubMed:8550586}. CC -!- DOMAIN: The PDZ-binding motif mediates the interaction with GRIP1. CC {ECO:0000250}. CC -!- DOMAIN: The C2 domain mediates pre-localization to the membrane prior CC to Ca(2+) import and non-selective Ca(2+)-mediated targeting to various CC cellular membranes. CC -!- DOMAIN: The PH domain is not a critical determinant of the membrane CC localization. The PH domain of isoform 4 is necessary and sufficient to CC inhibit enzyme activity of other PLC-delta enzymes. CC -!- DOMAIN: The GBA (G-alpha binding and activating) motif mediates binding CC to the alpha subunits of guanine nucleotide-binding proteins (G CC proteins). {ECO:0000250|UniProtKB:Q9BRC7}. CC -!- MISCELLANEOUS: [Isoform 4]: Inactive. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U16655; AAC52346.1; -; mRNA. DR EMBL; D50455; BAA09046.1; -; mRNA. DR RefSeq; NP_542419.1; NM_080688.1. [Q62711-1] DR AlphaFoldDB; Q62711; -. DR SMR; Q62711; -. DR STRING; 10116.ENSRNOP00000022234; -. DR BindingDB; Q62711; -. DR SwissLipids; SLP:000001069; -. DR iPTMnet; Q62711; -. DR PhosphoSitePlus; Q62711; -. DR PaxDb; 10116-ENSRNOP00000022234; -. DR GeneID; 140693; -. DR KEGG; rno:140693; -. DR UCSC; RGD:621025; rat. [Q62711-1] DR AGR; RGD:621025; -. DR CTD; 84812; -. DR RGD; 621025; Plcd4. DR VEuPathDB; HostDB:ENSRNOG00000016361; -. DR eggNOG; KOG0169; Eukaryota. DR HOGENOM; CLU_002738_0_2_1; -. DR InParanoid; Q62711; -. DR OrthoDB; 2900494at2759; -. DR PhylomeDB; Q62711; -. DR BRENDA; 3.1.4.11; 5301. DR Reactome; R-RNO-1855204; Synthesis of IP3 and IP4 in the cytosol. DR PRO; PR:Q62711; -. DR Proteomes; UP000002494; Chromosome 9. DR Bgee; ENSRNOG00000016361; Expressed in skeletal muscle tissue and 19 other cell types or tissues. DR ExpressionAtlas; Q62711; baseline and differential. DR GO; GO:0005783; C:endoplasmic reticulum; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; IEA:UniProtKB-KW. DR GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell. DR GO; GO:0005509; F:calcium ion binding; IEA:InterPro. DR GO; GO:0001965; F:G-protein alpha-subunit binding; ISS:UniProtKB. DR GO; GO:0004435; F:phosphatidylinositol phospholipase C activity; IDA:RGD. DR GO; GO:0007340; P:acrosome reaction; ISO:RGD. DR GO; GO:0035556; P:intracellular signal transduction; TAS:RGD. DR GO; GO:0016042; P:lipid catabolic process; IEA:UniProtKB-KW. DR CDD; cd00275; C2_PLC_like; 1. DR Gene3D; 2.60.40.150; C2 domain; 1. DR Gene3D; 1.10.238.10; EF-hand; 2. DR Gene3D; 3.20.20.190; Phosphatidylinositol (PI) phosphodiesterase; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR InterPro; IPR000008; C2_dom. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR011992; EF-hand-dom_pair. DR InterPro; IPR018247; EF_Hand_1_Ca_BS. DR InterPro; IPR002048; EF_hand_dom. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR InterPro; IPR001192; PI-PLC_fam. DR InterPro; IPR017946; PLC-like_Pdiesterase_TIM-brl. DR InterPro; IPR015359; PLC_EF-hand-like. DR InterPro; IPR000909; PLipase_C_PInositol-sp_X_dom. DR InterPro; IPR001711; PLipase_C_Pinositol-sp_Y. DR PANTHER; PTHR10336:SF31; 1-PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE PHOSPHODIESTERASE DELTA-4; 1. DR PANTHER; PTHR10336; PHOSPHOINOSITIDE-SPECIFIC PHOSPHOLIPASE C FAMILY PROTEIN; 1. DR Pfam; PF00168; C2; 1. DR Pfam; PF09279; EF-hand_like; 1. DR Pfam; PF00169; PH; 1. DR Pfam; PF00388; PI-PLC-X; 1. DR Pfam; PF00387; PI-PLC-Y; 1. DR PRINTS; PR00390; PHPHLIPASEC. DR SMART; SM00239; C2; 1. DR SMART; SM00054; EFh; 3. DR SMART; SM00233; PH; 1. DR SMART; SM00148; PLCXc; 1. DR SMART; SM00149; PLCYc; 1. DR SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1. DR SUPFAM; SSF47473; EF-hand; 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR SUPFAM; SSF51695; PLC-like phosphodiesterases; 1. DR PROSITE; PS50004; C2; 1. DR PROSITE; PS00018; EF_HAND_1; 1. DR PROSITE; PS50222; EF_HAND_2; 3. DR PROSITE; PS50003; PH_DOMAIN; 1. DR PROSITE; PS50007; PIPLC_X_DOMAIN; 1. DR PROSITE; PS50008; PIPLC_Y_DOMAIN; 1. DR Genevisible; Q62711; RN. PE 1: Evidence at protein level; KW Alternative splicing; Calcium; Cytoplasm; Endoplasmic reticulum; Hydrolase; KW Lipid degradation; Lipid metabolism; Membrane; Metal-binding; Nucleus; KW Phosphoprotein; Reference proteome; Repeat; Transducer. FT CHAIN 1..772 FT /note="1-phosphatidylinositol 4,5-bisphosphate FT phosphodiesterase delta-4" FT /id="PRO_0000306829" FT DOMAIN 16..124 FT /note="PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 134..169 FT /note="EF-hand 1" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT DOMAIN 170..205 FT /note="EF-hand 2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT DOMAIN 203..237 FT /note="EF-hand 3" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT DOMAIN 290..435 FT /note="PI-PLC X-box" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00270" FT DOMAIN 503..619 FT /note="PI-PLC Y-box" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00271" FT DOMAIN 619..746 FT /note="C2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00041" FT REGION 26..53 FT /note="Substrate binding" FT /evidence="ECO:0000250" FT REGION 445..486 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOTIF 213..243 FT /note="GBA" FT /evidence="ECO:0000250|UniProtKB:Q9BRC7" FT MOTIF 741..744 FT /note="PDZ-binding" FT COMPBIAS 468..486 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT ACT_SITE 305 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00270" FT ACT_SITE 350 FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00270" FT BINDING 147 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000305" FT BINDING 149 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000305" FT BINDING 151 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000305" FT BINDING 153 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000305" FT BINDING 158 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="1" FT /evidence="ECO:0000305" FT BINDING 183 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 185 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 187 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 189 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 194 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="2" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00448" FT BINDING 306 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /ligand_note="catalytic" FT /evidence="ECO:0000250" FT BINDING 335 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /ligand_note="catalytic" FT /evidence="ECO:0000250" FT BINDING 337 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="3" FT /ligand_note="catalytic" FT /evidence="ECO:0000250" FT BINDING 433 FT /ligand="substrate" FT /evidence="ECO:0000250" FT BINDING 435 FT /ligand="substrate" FT /evidence="ECO:0000250" FT BINDING 532 FT /ligand="substrate" FT /evidence="ECO:0000250" FT BINDING 559 FT /ligand="substrate" FT /evidence="ECO:0000250" FT BINDING 662 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000250" FT BINDING 686 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="4" FT /evidence="ECO:0000250" FT BINDING 715 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="5" FT /evidence="ECO:0000250" FT BINDING 716 FT /ligand="Ca(2+)" FT /ligand_id="ChEBI:CHEBI:29108" FT /ligand_label="5" FT /evidence="ECO:0000250" FT MOD_RES 445 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:22673903" FT MOD_RES 458 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:22673903" FT VAR_SEQ 424..487 FT /note="EQLRGKILVKGKKLRTIEVVESDKEEEELEKDEGSDLDPASAELDMQSQPES FT QEQASGNKSKNK -> VMKCPMSCLLICVHVLAQAPNSIPESILLPKR (in FT isoform 4)" FT /evidence="ECO:0000305" FT /id="VSP_028507" FT VAR_SEQ 487 FT /note="K -> KVMKCPMSCLLICVHVLAQAPNSIPESILLP (in isoform 2)" FT /evidence="ECO:0000303|PubMed:8550568" FT /id="VSP_028508" FT VAR_SEQ 487 FT /note="K -> KAPNSIPESILLP (in isoform 3)" FT /evidence="ECO:0000303|PubMed:8550568" FT /id="VSP_028509" FT MUTAGEN 36 FT /note="R->G: Only retains weak enzyme activity and FT abolishes the ability of isoform 4 to act as a negative FT regulator." FT /evidence="ECO:0000269|PubMed:9915823" FT MUTAGEN 714 FT /note="K->E: Abolishes affinity for POPC/POPS in the FT absence of Ca(2+); when associated with E-718." FT /evidence="ECO:0000269|PubMed:11706040" FT MUTAGEN 717 FT /note="S->D: Induces a larger Ca(2+)-dependence." FT /evidence="ECO:0000269|PubMed:11706040" FT MUTAGEN 718 FT /note="R->E: Abolishes affinity for POPC/POPS in the FT absence of Ca(2+); when associated with E-714." FT /evidence="ECO:0000269|PubMed:11706040" FT CONFLICT 395 FT /note="M -> ML (in Ref. 2; BAA09046)" FT /evidence="ECO:0000305" FT CONFLICT 416 FT /note="Missing (in Ref. 2; BAA09046)" FT /evidence="ECO:0000305" FT CONFLICT 425 FT /note="Missing (in Ref. 2; BAA09046)" FT /evidence="ECO:0000305" FT CONFLICT 757 FT /note="I -> H (in Ref. 2; BAA09046)" FT /evidence="ECO:0000305" SQ SEQUENCE 772 AA; 88967 MW; 5DD56D1D4AA21356 CRC64; MASQIQKLLT TNQDLLLMQK GTMMRKVRTK SWKKLRYFRL QDDGMTVWHG RHLESISKPT FSISDVERIR KGQDSELLRY LVEEFPLEQG FTIVFNGRRP NLDLVANSVE EAQTWMRGLQ LLVDLVARMN YQEQLDQMLR EWFQQADRNQ DSRMSFREAQ RLLLLMNVEM DEEYAFSLFQ EADVSQSNTL DSEEFVQFYK ALTKRTEIEE LFENFSSDKQ KLTLLEFVDF LREEQKESDH SSDLALKLID RYEPSENGRL LRVLSKDGFL SYLCSADGNI FNPDCLPIYQ DMTQPLSHYY INSSHNTYLL GDQFCGQSSV EGYIRALKRG CRCVEVDTWD GPDGEPVVYH GRTLTSRILF KDVLATLAQY AFQSSDYPLI LSLDNHCTWE QQKTMAHHLI AILGEQLLST TLEEQLIDIM PSPEQLRGKI LVKGKKLRTI EVVESDKEEE ELEKDEGSDL DPASAELDMQ SQPESQEQAS GNKSKNKKKF LLQSSTTILC PDLSALVVYL RTAPFCSFTH SKENYHIYDI SSFSESKAKN LIREAGNEFV QHNARQLCRV YPSGLRTDSS NYNPQEHWNV GCQMVAMNMQ TAGSAMDICD GLFRQNGGSG YVLKPEFLRD TQSSFNPMKP VSLYKAQILV VQVISGQRLP KVDKTKETTV VDPLVRVELY GVPEDTKQQE TSYVENNGIN PYWGETFYFQ IQVPELAMLR FVVKDYSRTS RNNFIGQYTL PWTCMKHGYR HVSLLSKDGT SLHPASIFVY TCMQEDLDMD EP //